[New surgical treatment options for bone tumors]

Selective Effects of Cold Atmospheric Plasma on Bone Sarcoma Cells and Human Osteoblasts

BACKGROUND

The use of cold atmospheric plasma (CAP) in oncology has been intensively investigated over the past 15 years as it inhibits the growth of many tumor cells. It is known that reactive oxidative species (ROS) produced in CAP are responsible for this effect. However, to translate the use of CAP into medical practice, it is essential to know how CAP treatment affects non-malignant cells. Thus, the current in vitro study deals with the effect of CAP on human bone cancer cells and human osteoblasts. Here, identical CAP treatment regimens were applied to the malignant and non-malignant bone cells and their impact was compared.

METHODS

Two different human bone cancer cell types, U2-OS (osteosarcoma) and A673 (Ewing's sarcoma), and non-malignant primary osteoblasts (HOB) were used. The CAP treatment was performed with the clinically approved kINPen MED. After CAP treatment, growth kinetics and a viability assay were performed. For detecting apoptosis, a caspase-3/7 assay and a TUNEL assay were used. Accumulated ROS was measured in cell culture medium and intracellular. To investigate the influence of CAP on cell motility, a scratch assay was carried out.

RESULTS

The CAP treatment showed strong inhibition of cell growth and viability in bone cancer cells. Apoptotic processes were enhanced in the malignant cells. Osteoblasts showed a higher potential for ROS resistance in comparison to malignant cells. There was no difference in cell motility between benign and malignant cells following CAP treatment.

CONCLUSIONS

Osteoblasts show better tolerance to CAP treatment, indicated by less affected viability compared to CAP-treated bone cancer cells. This points toward the selective effect of CAP on sarcoma cells and represents a further step toward the clinical application of CAP.

Dynamic relationship between postoperative infection and CRP, IL-6, and Livin in patients with bone tumors

BACKGROUND

The objective of the present study was to investigate the dynamic relationship between postoperative infection and levels of CRP, IL-6, and Livin in patients with bone tumors.

METHODS

A total of 126 patients with bone tumors admitted to our hospital from November 2013 to October 2015 were randomly selected and retrospectively analyzed. According to whether postoperative infection occurred, patients were divided into the infected group (N.=52) and the non-infected group (N.=74). Before surgery, and on the 1st, 3rd, 5th, 7th, and 10th day after surgery, the levels of serum CRP and IL-6 of patients in both groups were compared; the relative expression levels of Livin protein of patients in both groups were measured by Western blot.

RESULTS

After surgery, the levels of CRP and IL-6 of patients in both groups at all time points were significantly higher than those before surgery and the levels of CRP and IL-6 of the infected group were significantly higher than those of the non-infected group (P<0.05). The levels of CRP and IL-6 reached a peak on the 3rd day after surgery, and CRP declined rapidly. The levels of IL-6 declined slowly. On the 10th day after surgery, the levels of IL-6 of patients in both groups were higher than those before surgery and the levels of IL-6 of patients in the infected group were higher than those of the control group (P<0.05). The levels of Livin protein in patients of both groups were not significantly different (P>0.05).

CONCLUSIONS

The increase of the levels of CRP and IL-6 are closely related to infection. Livin has no close relationship with the occurrence of infection.